Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study (METAFORE)
Recruitment status was Recruiting
The efficacy of anti-VEGF treatments such as Bevacizumab in cases of HHT can be considered because of the molecular mechanisms implied in angiogenesis and HHT, as well as the mechanisms of action of this type of treatment. Two articles that have recently reported spectacular improvement thanks to Bevacizumab in patients with HHT complicated with severe liver involvement and cardiac effects support us in this sense.
Up to now, the only treatment recommended in the severe hepatic forms of HHT is a liver transplant, the disadvantages of which are both multiple and well known: long waiting lists, surgical morbidity and mortality, immunosuppressive treatment for life. Furthermore, treatment with Bevacizumab is not a contraindication, should the drug be ineffective, for a subsequent liver transplant if necessary.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study.|
- cardiac output measured at 3 months [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
- Evaluation at 6 and 12 months [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
|Study Start Date:||March 2009|
|Estimated Study Completion Date:||March 2012|
|Estimated Primary Completion Date:||March 2009 (Final data collection date for primary outcome measure)|
Study using a Gehan design, 7 patients will be included in the first phase and 18 additional patients will enter the second phase.
5 mg / kg every 14 days with a total of 6 injections.A two-phase Gehan method will be used with a first phase designed to eliminate a non effective treatment quickly and a second phase allowing assessment of efficacy.
Other Name: AVASTIN
|Contact: Sophie DUPUIS-GIROD, MD||4 72 41 32 95 ext 00 firstname.lastname@example.org|
|Hospices Civils de Lyon||Recruiting|
|Contact: Sophie DUPUIS-GIROD, MD 4 72 41 32 95 ext 00 33 email@example.com|
|Principal Investigator:||Sophie DUPUIS-GIROD, MD||Hospices Civils de Lyon|